Viral and immunologic evaluation of smokers with severe COVID-19

Sci Rep. 2023 Oct 19;13(1):17898. doi: 10.1038/s41598-023-45195-z.

Abstract

Smoking negatively affects B cell function and immunoglobulin levels, but it is unclear if this immune dysfunction contributes to the risk of severe COVID-19 in smokers. We evaluated binding IgM, IgA and IgG antibodies to spike and receptor binding domain antigens, and used a pseudovirus assay to quantify neutralization titers in a set of 27 patients with severe COVID-19. We found no significant differences between binding and neutralization antibody responses for people with a smoking history and people who never smoked. High plasma viral load, but not antibody titers, was linked to an increased risk of death. Humoral immune dysfunction was not a major driver of severe COVID-19 in smokers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antibody Formation
  • COVID-19*
  • Humans
  • Immunoglobulin M
  • SARS-CoV-2
  • Smokers

Substances

  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Immunoglobulin M